High infection rates and a better understanding of underlying health impact increase the demand for screening for STI organisms including Chlamydia trachomatis (CT), Neisseria gonorrhoeae (GC), Herpes Simplex Virus 1 & 2 (HSV1 & HSV2)*, and Human Papillomavirus (HPV)* in targeted populations around the world.
This demand comes at a time when laboratories are challenged by the pressure to contain healthcare costs, a shortage of trained personnel and expectations to deliver more, and higher quality results.
BD has developed solutions that fulfill your screening and diagnostic needs with :
|New Amplified Molecular Tests Launched to Help Improve Diagnosis and Treatment of Herpes Patients »
|BD Viper™ with XTR™ technology »|